Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $5.1 million.

  • Corcept Therapeutics' Change in Receivables fell 1391.16% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 6049.58%. This contributed to the annual value of $12.9 million for FY2024, which is 2768.73% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Change in Receivables stood at $5.1 million, which was down 1391.16% from $2.7 million recorded in Q2 2025.
  • Corcept Therapeutics' Change in Receivables' 5-year high stood at $20.4 million during Q1 2024, with a 5-year trough of -$7.7 million in Q2 2024.
  • For the 5-year period, Corcept Therapeutics' Change in Receivables averaged around $2.3 million, with its median value being $1.5 million (2023).
  • Data for Corcept Therapeutics' Change in Receivables shows a peak YoY increase of 125966.67% (in 2024) and a maximum YoY decrease of 19192500.0% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Change in Receivables stood at $1.1 million in 2021, then skyrocketed by 47.09% to $1.6 million in 2022, then surged by 295.44% to $6.5 million in 2023, then tumbled by 188.36% to -$5.7 million in 2024, then skyrocketed by 188.17% to $5.1 million in 2025.
  • Its Change in Receivables was $5.1 million in Q3 2025, compared to $2.7 million in Q2 2025 and $7.8 million in Q1 2025.